![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Sarcomas are a rare family of heterogeneous tumors of mesenchymal origin characterized by their bad prognosis. In addition, limited active therapeutic options are available. The cytotoxic drug gemcitabine and the inhibition of the mTOR pathway have demonstrated modest activity in sarcomas as monotherapy. However, preclinical data suggest that the combination of both treatments results in enhanced antitumor activity. In vitro and in vivo experiments with the mTOR inhibitor sirolimus plus gemcitabine showed dramatic results in preclinical models of sarcoma. Moreover, a Phase I study demonstrated the favorable toxicity profile of the combination in patients with advanced solid tumors. Therefore, treatment with sirolimus plus gemcitabine deserves further investigation in sarcomas.
Financial & competing interests disclosure
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.